“…It appears that in vitro metronidazole resistance may in part be overcome in vivo by quadruple therapy of longer duration (14 days) involving a higher dose of metronidazole [6,32]. A higher cure rate has also been reported for 1600 mg of metronidazole used in combination with amoxicillin – a regimen known as English triple therapy [33]. Another rescue treatment currently used in Germany and other European countries [4,34,35] is dual therapy with high‐dose omeprazole (120 mg daily) and amoxicillin (2.25–3 g), which was developed in the mid‐1990s [36].…”
The data of this pilot study suggest a better than 80% efficacy of the new 7-day levofloxacin triple therapy, which is within the range of the French triple therapy in patients with MET- and CLA-susceptible strains. The data suggest that the new levofloxacin triple therapy may also be an option in patients with MET- and CLA-resistant H. pylori strains.
“…It appears that in vitro metronidazole resistance may in part be overcome in vivo by quadruple therapy of longer duration (14 days) involving a higher dose of metronidazole [6,32]. A higher cure rate has also been reported for 1600 mg of metronidazole used in combination with amoxicillin – a regimen known as English triple therapy [33]. Another rescue treatment currently used in Germany and other European countries [4,34,35] is dual therapy with high‐dose omeprazole (120 mg daily) and amoxicillin (2.25–3 g), which was developed in the mid‐1990s [36].…”
The data of this pilot study suggest a better than 80% efficacy of the new 7-day levofloxacin triple therapy, which is within the range of the French triple therapy in patients with MET- and CLA-susceptible strains. The data suggest that the new levofloxacin triple therapy may also be an option in patients with MET- and CLA-resistant H. pylori strains.
OMC is a well-tolerated, effective therapy for H. pylori eradication and duodenal ulcer healing in this region despite the high metronidazole resistance rate. OAM is less effective, largely due to the impact of metronidazole resistance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.